Assaying cardiac biomarkers for toxicity testing using biosensing and cardiomyocytes derived from human embryonic stem cells
2010 (English)In: JOURNAL OF BIOTECHNOLOGY, ISSN 0168-1656, Vol. 150, no 1, 175-181 p.Article in journal (Refereed) Published
Human embryonic stem cell (hESC) derived cardiomyocytes are in the present study being used for testing drug-induced cardiotoxicity in a biosensor set-up. The design of an in vitro testing alternative provides a novel opportunity to surpass previous methods based on rodent cells or cell lines due to its significantly higher toxicological relevance. In this report we demonstrate how hESC-derived cardiomyocytes release detectable levels of two clinically decisive cardiac biomarkers, cardiac troponin T and fatty acid binding protein 3, when the cardiac cells are exposed to the well-known cardioactive drug compound. doxorubicin. The release is monitored by the immuno-biosensor technique surface plasmon resonance, particularly appropriate due to its capacity for parallel and high-throughput analysis in complex media.
Place, publisher, year, edition, pages
Elsevier Science B.V., Amsterdam. , 2010. Vol. 150, no 1, 175-181 p.
In vitro toxicity testing, hESC-derived cardiomyocytes, Doxorubicin, Biosensors, Surface plasmon resonance. SPR
Engineering and Technology
IdentifiersURN: urn:nbn:se:liu:diva-62153DOI: 10.1016/j.jbiotec.2010.06.023ISI: 000283693600025OAI: oai:DiVA.org:liu-62153DiVA: diva2:371280